How effective and how safe is naltrexone for preventing alcohol consumption in individuals with alcohol-use disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Naltrexone for Alcohol Use Disorder: Effectiveness and Safety

Naltrexone is moderately effective for preventing alcohol relapse and reducing heavy drinking, with short-term treatment lowering the risk of relapse by approximately 17%, though it carries a risk of hepatocellular injury that requires careful monitoring, particularly at higher doses. 1

Effectiveness

Reduction in Heavy Drinking

Naltrexone demonstrates clear efficacy in reducing alcohol consumption among patients with alcohol use disorder:

  • Reduces heavy drinking days by 25% compared to placebo when combined with psychosocial interventions 2
  • Decreases overall drinking days by approximately 4% (MD -3.89 days) 2
  • Lowers total alcohol consumption by roughly 11 units (MD -10.83) 2
  • In controlled trials, abstinence rates reached 51% vs 23% with placebo, and relapse rates were 31% vs 60% 3

Clinical Context and Limitations

The evidence shows naltrexone works best when:

  • Combined with counseling and psychosocial support - medication alone is insufficient 1
  • Patients have already achieved initial abstinence - naltrexone maintains rather than induces abstinence 1
  • External compliance support exists - the drug does not reinforce its own use like methadone 3

Critical caveat: Naltrexone is "not uniformly helpful to all patients" and produces only "a modest improvement in the outcome of conventional treatment" 3. The effect sizes, while statistically significant, are moderate in magnitude 2.

Safety Concerns

Hepatotoxicity - The Primary Risk

Naltrexone has been shown to cause hepatocellular injury, which is the most significant safety concern 1:

  • Dose-dependent liver toxicity occurs at higher doses (up to 300 mg/day in studies) 3
  • At therapeutic doses (50 mg/day), hepatotoxicity risk exists but is less pronounced
  • Baseline liver function tests and monitoring every 3-6 months are mandatory 4

Contraindications in Liver Disease

Multiple guidelines explicitly state:

  • Naltrexone is NOT recommended in patients with alcoholic liver disease (ALD) due to hepatotoxicity risk 5, 6
  • Contraindicated in patients with acute hepatitis or liver failure 6
  • For patients with cirrhosis or advanced liver disease, baclofen is the preferred alternative 1, 5

Common Adverse Effects

The most frequent side effects are generally mild 3:

  • Gastrointestinal: Nausea (10% incidence, RD 0.10), vomiting (3%)
  • Neurological: Headache (7%), dizziness (4%), sedation/daytime sleepiness (9%, RD 0.09)
  • Psychiatric: Nervousness (4%), anxiety (2%), insomnia (3%)
  • Discontinuation rate: Approximately 5% of patients stop due to nausea 3

Other Safety Considerations

  • Cannot be used with concurrent opioid therapy - blocks pain relief from opioid medications 4
  • Risk of precipitated withdrawal if patient is not completely opioid-free 3
  • Depression and suicidal ideation rates (0-15%) are similar to placebo (0-17%), suggesting no causal relationship 3

Practical Prescribing Algorithm

Patient Selection

First-line candidates 1:

  • Alcohol-dependent patients who have achieved initial detoxification/abstinence
  • Normal liver function (no evidence of alcoholic liver disease)
  • Motivated patients with psychosocial support structure
  • Not requiring opioid pain medications

Avoid or use alternative 5, 6:

  • Advanced alcoholic liver disease → use baclofen instead
  • Liver function tests >3× normal or elevated bilirubin → use acamprosate instead
  • Active opioid use or chronic pain requiring opioids → contraindicated

Dosing Regimen

Standard oral naltrexone 3:

  • 50 mg once daily, or
  • 100 mg on Monday/Wednesday, 150 mg on Friday (alternative schedule)
  • Duration: 3-6 months minimum, up to 12 months

Long-acting injectable (Vivitrol) 7:

  • 380 mg intramuscular monthly
  • Shows 25% reduction in heavy drinking days (superior to 190 mg dose)
  • Better treatment persistence than oral formulation 8

Monitoring Requirements

  • Baseline liver function tests before initiation 4
  • Repeat LFTs every 3-6 months during treatment 4
  • Assess drinking patterns and psychosocial support adherence regularly

Comparative Effectiveness

Naltrexone vs. Acamprosate: Recent evidence suggests acamprosate may be superior for maintaining abstinence in primary care settings, with moderate-quality evidence supporting its use 9. Naltrexone and acamprosate showed no significant difference in a large RCT 1.

Naltrexone vs. Nalmefene: Both reduce heavy drinking days and total alcohol consumption, though nalmefene can be used "as needed" rather than daily 10, 11.

Injectable vs. Oral: Long-acting injectable naltrexone demonstrates 94% higher treatment persistence (OR 1.94) compared to oral formulation, particularly at 3 and 6 months 8, though healthcare utilization outcomes (ED visits, hospitalizations) show no difference.

Bottom Line for Clinical Practice

Use naltrexone as an adjunct to counseling in alcohol-dependent patients who have achieved initial abstinence and have normal liver function. The drug provides modest but meaningful reductions in heavy drinking and relapse risk. Absolutely avoid in patients with alcoholic liver disease - choose baclofen or acamprosate instead. Monitor liver function regularly, and recognize that the injectable formulation may improve adherence in appropriate candidates. The medication works best within a comprehensive treatment program, not as monotherapy.

Related Questions

In a patient with acute alcohol withdrawal, when is it appropriate to initiate naltrexone, what dosing regimen should be used for relapse prevention, and what contraindications must be considered?
In a patient with binge drinking who is taking naltrexone (50 mg oral daily or 380 mg intramuscular monthly) but has not experienced reduced alcohol consumption, what are the possible reasons for lack of efficacy and what alternative pharmacologic treatments should be considered?
What are alternative medications to naltrexone for treating opioid use disorder and alcohol use disorder?
What is the appropriate naltrexone dosing for alcohol use disorder, including oral and extended‑release injectable forms, and associated contraindications?
What is the usual dose of naltrexone for treating opioid dependence or alcohol use disorder?
I am a 30-year-old male with multiple sclerosis, up to date on childhood vaccines, Tdap, and influenza vaccine, and I plan to start the disease-modifying therapy ofatumumab (Kesimpta). What vaccinations do the CDC or Multiple Sclerosis Society recommend before initiating therapy, and how does ofatumumab affect immune function?
What are the current recommendations for coronary artery calcium (CAC) scoring in asymptomatic adults aged 40–75 years?
What components are included in a comprehensive metabolic panel (CMP)?
Can dexmedetomidine be administered to a patient with meningitis?
What antihypertensive therapy is recommended for patients with autosomal dominant polycystic kidney disease?
Should imatinib be continued in a chronic myeloid leukemia patient who presents with diarrhea, abdominal pain, marked leukocytosis, normal lactate, stable vital signs, negative Clostridioides difficile PCR, and is receiving empiric piperacillin‑tazobactam?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.